(Montisera Ltd, Turku, Finland; September 17, 2019) – Montisera Ltd, a Finnish development company focused on developing and commercialising bioactive compounds, announces today that the Japanese and Russian patent offices have granted patent for the Company’s product Qusitol®, “Wood hemicelluloses for use in the treatment of lower urinary tract symptoms and diseases”. The granted patent is based on applications drafted and prosecuted by the Turku office team, from Oy Kolster Ab. Kolster is the leading intellectual property service agency in Finland.
The origin of Montisera’s compound is deep in Finnish nature as it is extracted from spruce (Picea abies), the Green, renewable Gold of Finland. ”As we already stated in 2016 when the Finnish patent was granted, It is exceptional to have a patent issued for an extract like this. Now with the Russian and Japanese patents granted, the value and business potential for the product has grown to a next level”, says Heikki Vuorikoski, Business Development director of Montisera and one of the inventors of the product.
The company has pending patent applicationsfor the spruce extract also in Canada, China, USA and EPO. In China and EPO the next official actions are expected already within a year.
Lower urinary tract (LUT) diseases cover all diseases that cause lower urinary tract symptoms, including various functional disorders and diseases of the bladder, the prostate and the urethra. The most common diseases associated with LUT symptoms related to the prostate in men are prostatitis, an umbrella term referring to several types of prostatitis, such as chronic prostatitis/chronic pelvic pain syndrome, and benign prostatic hyperplasia (BPH). In women, common diseases related to the bladder are interstitial cystitis/painful bladder syndrome (IC/PBS) and urinary incontinence.
Matti Kurvinen, Chairman of the Board of Montisera: “Despite the prevalence and incidence of these diseases and symptoms, there is still a lack of effective treatment. Montisera is seeking partners in order to take this potential finding further for the patients’ relief and treatment”.
For more information please contact:
Business Development Director Heikki Vuorikoski, tel. +358 40 7562 427
This news release may contain forward-looking statements that reflect Montisera’s current expectations regarding future events, including statements about whether the subject patent would be issued and adequately protect Montisera against competition, Montisera’s plan to protect the commercial potential of its product candidates, and the future status of pending patent applications. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein, and depend on a number of factors, including (inter alia) the success of Montisera’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of products by consumer and medical professionals. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which are effective only as of the date hereof. Montisera undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.